{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:09:04Z","timestamp":1791662944327,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-12270-0","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:33:17Z","timestamp":1767796397000},"page":"4403-4413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic performance of MRI in predicting pathological response in patients with triple-negative breast carcinomas undergoing neoadjuvant chemotherapy and immunotherapy"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-6422","authenticated-orcid":false,"given":"Soraia Quaranta","family":"Dami\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Barbosa","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah Wanderley","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Cardona","family":"Felipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"De Brot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange Moraes","family":"Sanches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana Baroni","family":"Makdissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almir Galv\u00e3o Vieira","family":"Bitencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"12270_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/J.SOC.2014.03.011","volume":"23","author":"KA Ban","year":"2014","unstructured":"Ban KA, Godellas CV (2014) Epidemiology of breast cancer. Surg Oncol Clin N Am 23:409\u2013422. https:\/\/doi.org\/10.1016\/J.SOC.2014.03.011","journal-title":"Surg Oncol Clin N Am"},{"key":"12270_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/CAAC.21660","journal-title":"CA Cancer J Clin"},{"key":"12270_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/ANNUREV-PATHOL-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS (2022) Pathogenesis of triple-negative breast cancer. Annu Rev Pathol 17:181\u2013204. https:\/\/doi.org\/10.1146\/ANNUREV-PATHOL-042420-093238","journal-title":"Annu Rev Pathol"},{"key":"12270_CR4","doi-asserted-by":"publisher","unstructured":"Adrada BE, Moseley TW, Kapoor MM et al (2023) Triple-negative breast cancer: histopathologic features, genomics, and treatment. Radiographics. https:\/\/doi.org\/10.1148\/rg.230034","DOI":"10.1148\/rg.230034"},{"key":"12270_CR5","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414\u20134422. https:\/\/doi.org\/10.1200\/JCO.2007.10.6823","journal-title":"J Clin Oncol"},{"key":"12270_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/BD-210023","volume":"41","author":"S Jafferbhoy","year":"2022","unstructured":"Jafferbhoy S, Gowda SM, Kabeer KK et al (2022) Role of MRI in predicting response to neo-adjuvant systemic therapy (NAST) in breast cancer. Breast Dis 41:165\u2013173. https:\/\/doi.org\/10.3233\/BD-210023","journal-title":"Breast Dis"},{"key":"12270_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1148\/radiol.2015150089","volume":"278","author":"MS Bae","year":"2016","unstructured":"Bae MS, Moon H-G, Han W et al (2016) Early stage triple-negative breast cancer: imaging and clinical-pathologic factors associated with recurrence. Radiology 278:356\u2013364. https:\/\/doi.org\/10.1148\/radiol.2015150089","journal-title":"Radiology"},{"key":"12270_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/S10334-021-00941-0","volume":"34","author":"A Nemeth","year":"2021","unstructured":"Nemeth A, Chaudet P, Leporq B et al (2021) Multicontrast MRI-based radiomics for the prediction of pathological complete response to neoadjuvant chemotherapy in patients with early triple negative breast cancer. MAGMA 34:833\u2013844. https:\/\/doi.org\/10.1007\/S10334-021-00941-0","journal-title":"MAGMA"},{"key":"12270_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1148\/RADIOL.2019182947","volume":"292","author":"RM Mann","year":"2019","unstructured":"Mann RM, Cho N, Moy L (2019) Breast MRI: state of the art. Radiology 292:520\u2013536. https:\/\/doi.org\/10.1148\/RADIOL.2019182947","journal-title":"Radiology"},{"key":"12270_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y et al (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15:121. https:\/\/doi.org\/10.1186\/s13045-022-01341-0","journal-title":"J Hematol Oncol"},{"key":"12270_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387:217\u2013226. https:\/\/doi.org\/10.1056\/NEJMoa2202809","journal-title":"N Engl J Med"},{"key":"12270_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"12270_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1200\/JCO.2022.40.16_suppl.512","volume":"40","author":"L Spring","year":"2022","unstructured":"Spring L, Tolaney SM, Desai NV et al (2022) Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial. J Clin Oncol 40:512. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.512","journal-title":"J Clin Oncol"},{"key":"12270_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMOA2112651\/SUPPL_FILE\/NEJMOA2112651_DATA-SHARING.PDF","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R et al (2022) Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 386:556\u2013567. https:\/\/doi.org\/10.1056\/NEJMOA2112651\/SUPPL_FILE\/NEJMOA2112651_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"12270_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","volume":"36","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Ballinger M, Lyons B et al (2018) Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol 36:850\u2013858. https:\/\/doi.org\/10.1200\/JCO.2017.75.1644","journal-title":"J Clin Oncol"},{"key":"12270_CR16","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med 142:1364\u20131382. https:\/\/doi.org\/10.5858\/arpa.2018-0902-SA","journal-title":"Arch Pathol Lab Med"},{"key":"12270_CR17","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol 38:1346\u20131366. https:\/\/doi.org\/10.1200\/JCO.19.02309","journal-title":"J Clin Oncol"},{"key":"12270_CR18","unstructured":"D\u2019Orsi CJ, Sickles EA, Mendelson EB, Morris EA (2014) 2013 ACR BI-RADS Atlas: breast imaging reporting and data system. American College of Radiology. American College of Radiology"},{"key":"12270_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"12270_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","volume":"11","author":"H Wang","year":"2019","unstructured":"Wang H, Yee D (2019) I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer. Curr Breast Cancer Rep 11:303\u2013310. https:\/\/doi.org\/10.1007\/s12609-019-00334-2","journal-title":"Curr Breast Cancer Rep"},{"key":"12270_CR21","doi-asserted-by":"publisher","unstructured":"Cai W, Jing M, Gu Y et al (2022) Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.984666","DOI":"10.3389\/fimmu.2022.984666"},{"key":"12270_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48480-1","volume":"15","author":"W Beckabir","year":"2024","unstructured":"Beckabir W, Zhou M, Lee JS et al (2024) Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nat Commun 15:4448. https:\/\/doi.org\/10.1038\/s41467-024-48480-1","journal-title":"Nat Commun"},{"key":"12270_CR23","doi-asserted-by":"publisher","unstructured":"Zhang N, Li C, Zhao Z et al (2025) Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1497004","DOI":"10.3389\/fimmu.2025.1497004"},{"key":"12270_CR24","doi-asserted-by":"publisher","first-page":"7549","DOI":"10.1245\/s10434-023-14123-w","volume":"30","author":"T Chen","year":"2023","unstructured":"Chen T, Cao Z, Sun Y et al (2023) Neoadjuvant chemoimmunotherapy increases tumor immune lymphocytes infiltration in resectable non-small cell lung cancer. Ann Surg Oncol 30:7549\u20137560. https:\/\/doi.org\/10.1245\/s10434-023-14123-w","journal-title":"Ann Surg Oncol"},{"key":"12270_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10549-025-07650-5","volume":"212","author":"J Spriet","year":"2025","unstructured":"Spriet J, Miled AB, Mailliez A et al (2025) Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and performance of ultrafast sequences. Breast Cancer Res Treat 212:195\u2013203. https:\/\/doi.org\/10.1007\/s10549-025-07650-5","journal-title":"Breast Cancer Res Treat"},{"key":"12270_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.6004\/jadpro.2020.11.7.6","volume":"11","author":"ES Waxman","year":"2020","unstructured":"Waxman ES, Lee Gerber D (2020) Pseudoprogression and immunotherapy phenomena. J Adv Pract Oncol 11:723\u2013731. https:\/\/doi.org\/10.6004\/jadpro.2020.11.7.6","journal-title":"J Adv Pract Oncol"},{"key":"12270_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2217\/imt-2023-0158","volume":"16","author":"X Zhao","year":"2024","unstructured":"Zhao X, Ma K, Ma X et al (2024) Imaging findings can\u2019t mean everything in the era of immunotherapy: a case report and literature review. Immunotherapy 16:99\u2013106. https:\/\/doi.org\/10.2217\/imt-2023-0158","journal-title":"Immunotherapy"},{"key":"12270_CR28","doi-asserted-by":"publisher","unstructured":"Drisis S, Metens T, Ignatiadis M, Stathopoulos K, Chao SL, Lemort M (2016) Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy. Eur Radiol 26:1474\u20131484. https:\/\/doi.org\/10.1007\/S00330-015-3948-0","DOI":"10.1007\/S00330-015-3948-0"},{"key":"12270_CR29","doi-asserted-by":"publisher","first-page":"6440952","DOI":"10.1155\/2022\/6440952","volume":"2022","author":"L Li","year":"2022","unstructured":"Li L, Zhang Q, Qian C, Lin H (2022) Impact of preoperative magnetic resonance imaging on surgical outcomes in women with invasive breast cancer: a systematic review and meta-analysis. Int J Clin Pract 2022:6440952. https:\/\/doi.org\/10.1155\/2022\/6440952","journal-title":"Int J Clin Pract"},{"key":"12270_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1590\/0100-3984.2018.0149","volume":"52","author":"EMS Negr\u00e3o","year":"2019","unstructured":"Negr\u00e3o EMS, Bitencourt AGV, de Souza JA, Marques EF (2019) Accuracy of breast magnetic resonance imaging in evaluating the response to neoadjuvant chemotherapy: a study of 310 cases at a cancer center. Radiol Bras 52:299\u2013304. https:\/\/doi.org\/10.1590\/0100-3984.2018.0149","journal-title":"Radiol Bras"},{"key":"12270_CR31","doi-asserted-by":"publisher","unstructured":"Zhang Y, Shen J, Wu S, Zhou Y, Shao Z, Liu G (2020) The use of a second core needle biopsy to predict response to neoadjuvant chemotherapy in breast cancer patients, especially in the HER2-positive population. Surgery 168:1115\u20131121. https:\/\/doi.org\/10.1016\/j.surg.2020.06.045","DOI":"10.1016\/j.surg.2020.06.045"},{"key":"12270_CR32","doi-asserted-by":"publisher","first-page":"e195410","DOI":"10.1001\/jamasurg.2019.5410","volume":"155","author":"M Golshan","year":"2020","unstructured":"Golshan M, Loibl S, Wong SM et al (2020) Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer. JAMA Surg 155:e195410. https:\/\/doi.org\/10.1001\/jamasurg.2019.5410","journal-title":"JAMA Surg"},{"key":"12270_CR33","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/jmri.28219","volume":"56","author":"BC Musall","year":"2022","unstructured":"Musall BC, Adrada BE, Candelaria RP et al (2022) Quantitative apparent diffusion coefficients from peritumoral regions as early predictors of response to neoadjuvant systemic therapy in triple-negative breast cancer. J Magn Reson Imaging 56:1901\u20131909. https:\/\/doi.org\/10.1002\/jmri.28219","journal-title":"J Magn Reson Imaging"},{"key":"12270_CR34","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12282-018-0834-z","volume":"25","author":"H Nguyen-Thu","year":"2018","unstructured":"Nguyen-Thu H, Hanaoka H, Nakajima T et al (2018) Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and 18F-FDG-PET. Breast Cancer 25:334\u2013342. https:\/\/doi.org\/10.1007\/s12282-018-0834-z","journal-title":"Breast Cancer"},{"key":"12270_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52785-3","volume":"9","author":"NP Pereira","year":"2019","unstructured":"Pereira NP, Curi C, Os\u00f3rio CABT et al (2019) Diffusion-weighted magnetic resonance imaging of patients with breast cancer following neoadjuvant chemotherapy provides early prediction of pathological response\u2014a prospective study. Sci Rep 9:16372. https:\/\/doi.org\/10.1038\/s41598-019-52785-3","journal-title":"Sci Rep"},{"key":"12270_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejso.2021.10.016","volume":"48","author":"RAW Ploumen","year":"2022","unstructured":"Ploumen RAW, Keymeulen KBMI, Kooreman LFS et al (2022) The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: a nationwide retrospective study. Eur J Surg Oncol 48:60\u201366. https:\/\/doi.org\/10.1016\/j.ejso.2021.10.016","journal-title":"Eur J Surg Oncol"},{"key":"12270_CR37","doi-asserted-by":"publisher","unstructured":"Ploumen RAW, de Mooij CM, Gommers S, Keymeulen KBMI, Smidt ML, van Nijnatten TJA (2023) Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis. Eur Radiol 33:5423\u20135435. https:\/\/doi.org\/10.1007\/s00330-023-09547-7","DOI":"10.1007\/s00330-023-09547-7"},{"key":"12270_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinimag.2022.05.002","volume":"89","author":"M Kwon","year":"2022","unstructured":"Kwon M, Chu J, Kook SH, Kim EY (2022) Factors associated with radiologic-pathologic discordance in magnetic resonance imaging after neoadjuvant chemotherapy for breast cancer. Clin Imaging 89:1\u20139. https:\/\/doi.org\/10.1016\/j.clinimag.2022.05.002","journal-title":"Clin Imaging"},{"key":"12270_CR39","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1148\/rg.2021200134","volume":"41","author":"B Reig","year":"2021","unstructured":"Reig B, Lewin AA, Du L et al (2021) Breast MRI for evaluation of response to neoadjuvant therapy. Radiographics 41:665\u2013679. https:\/\/doi.org\/10.1148\/rg.2021200134","journal-title":"Radiographics"},{"key":"12270_CR40","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1016\/j.jacr.2024.02.021","volume":"21","author":"ES McDonald","year":"2024","unstructured":"McDonald ES, Scheel JR, Lewin AA et al (2024) ACR Appropriateness Criteria\u00ae imaging of invasive breast cancer. J Am Coll Radiol 21:S168\u2013S202. https:\/\/doi.org\/10.1016\/j.jacr.2024.02.021","journal-title":"J Am Coll Radiol"},{"key":"12270_CR41","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/jcrt.jcrt_1050_22","volume":"19","author":"L Zhang","year":"2023","unstructured":"Zhang L, Tian T, Zhang Y et al (2023) Pseudoprogression during immunotherapy for gastric adenocarcinoma: a case report and literature review. J Cancer Res Ther 19:144\u2013149. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1050_22","journal-title":"J Cancer Res Ther"},{"key":"12270_CR42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(24)00104-9","volume":"25","author":"A van der Voort","year":"2024","unstructured":"van der Voort A, Louis FM, van Ramshorst MS et al (2024) MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II\u2013III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study. Lancet Oncol 25:603\u2013613. https:\/\/doi.org\/10.1016\/S1470-2045(24)00104-9","journal-title":"Lancet Oncol"},{"key":"12270_CR43","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1158\/0008-5472.CAN-22-1329","volume":"82","author":"C Wu","year":"2022","unstructured":"Wu C, Jarrett AM, Zhou Z et al (2022) MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. Cancer Res 82:3394\u20133404. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-1329","journal-title":"Cancer Res"},{"key":"12270_CR44","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","volume":"403","author":"JM P\u00e9rez-Garc\u00eda","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda JM, Cort\u00e9s J, Ruiz-Borrego M et al (2024) 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet 403:1649\u20131659. https:\/\/doi.org\/10.1016\/S0140-6736(24)00054-0","journal-title":"Lancet"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12270-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-12270-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12270-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:26:22Z","timestamp":1779798382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-12270-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["12270"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-12270-0","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Dr. Almir Galv\u00e3o Vieira Bitencourt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}